Skip to main content

Table 3 Relationships between serum sCD40L and clinicopathological characteristics of PDAC, compared with CA19-9 in the validation dataset

From: Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma

 

sCD40L

CA19-9

γs(p- value)

γs(p- value)

Gender (Male: Female)

-0.046 (0.740)

-0.213 (0.126)

Age (≤40, > 40 & ≤60, > 60)

0.076 (0.581)

-0.181 (0.194)

T-stage (T1, T2, T3 ,T4)

0.194 (0.156)

0.095 (0.501)

Node metastasis (N0, N1)

-0.146 (0.289)

0.362 (0.008)

Distant metastasis (M0, M1)

0.294(0.030)

0.425 (0.002)

Overall stage (I, II, III, IV)

0.319 (0.017)

0.431 (0.001)

Size (≤2 cm, > 2 cm & ≤5 cm, > 5 cm)

0.035 (0.801)

0.179 (0.201)

Unresectability*

0.342 (0.011)

0.269 (0.051)

  1. sCD40L, soluble CD40 ligand; CA19-9, carbohydrate antigen 19–9; PDAC, pancreatic ductal adenocarcinoma.
  2. γs, Spearman’s correlation coefficient.
  3. p < 0.05 (two-tailed) was considered to be statistically significant.
  4. Statistically significant values are given in bold type.
  5. *A tumor is defined as unresectable when a tumor invades celiac axis or superior mesenteric artery (T4, N0-1, M0, stage III), or metastasizes to distant sites (T1-4, N0-1, M1, stage IV).
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us